

## Special Issue

# Successes and Barriers of HPV Vaccination and Cervical Screening on Cervical Cancer Elimination

### Message from the Guest Editor

Dear colleagues, Cervical cancer is the fourth most common cancer in women, with over 570,000 new cases a year. The primary cause of cervical pre-cancer and cancer is infection with a high-risk or oncogenic human papillomavirus (HPV). Cervical cancer is a preventable disease, with several strategies for prevention and treatment, but it is mostly prevented through vaccination efforts and is curable if detected early at pre-cancer stages. In November 2020, WHO announced the “Global strategy to accelerate the elimination of cervical cancer as a public health problem”. It has suggested vaccinating 90 percent of girls against multiple strains of HPV by 15 years of age, screening 70 percent of women for cervical cancer at ages 35 and 45, and giving care to 90 percent of women with cervical pre-cancer lesions or cancer (90-70-90) targets to meet the cervical cancer elimination goal by 2030.

---

### Guest Editor

Prof. Sadeep Shrestha

Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA

---

### Deadline for manuscript submissions

closed (30 September 2022)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/si/69967](https://mdpi.com/si/69967)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)